Developer of drug therapy intended to treat acute bleeding conditions. The company's therapy helps in stabilizing blood clots, increasing anti-bleeding treatment time-window beyond 3 hours, minimizing blood toxicity in the brain and has reduced side effects, enabling physicians to treat their patients in an enhanced way.
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
3. Out of Business | 0000 | Completed | Out of Business | |||
2. Angel (individual) | 18-Jul-2016 | 000 | 0000 | Completed | Startup | |
1. Accelerator/Incubator | $3M | $3M | Completed | Startup |
Name | Title | Board Seat | Contact Info |
---|---|---|---|
Amos Ofer Ph.D | Chief Executive Officer | ||
Abd Higazi MD | Co-Founder & Chief Scientific Officer | ||
Nuha Higazi Ph.D | Co-Founder & Chief Technology Officer |
Name | Representing | Role | Since |
---|---|---|---|
Noa Shelach Ph.D | PamBio | Board Member | 000 0000 |